News
Moderna's new COVID-19 vaccine mNexspike approved by FDA, but there's a limit on who can use it
The FDA's approval was based on a study of 11,400 people age 12 and older that compared the new low-dose vaccine with Moderna's existing vaccine. It found the new vaccine was safe and was at least as effective - and more by some measures - than the original shot, the company said.
Moderna's mNexspike COVID vaccine approved by FDA for older adults and at-risk groups after Phase 3 trial shows improved ...
Moderna stock jumped 4.93% to $27.87 in premarket trading after the FDA granted limited approval for mNEXSPIKE, a new COVID-19 vaccine requiring only one-fifth the dose of the company's current ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback